Skip to content
value.today
CAMP Nine, Inc. logo

CAMP Nine, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2012
Total raised
$11 M
1 round on record
Latest round
$11 M
Jun 2014
First round on record
Jun 2014
Today
Went public
See the company page

CAMP Nine, Inc. is listed today as Relmada Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of CAMP Nine, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$8 MPrivate placement after listing$2 to $10 million

CAMP Nine, Inc.: Private sale, Jun 2019

Investors in this round

116 investors had bought by the notice of Jul 10, 2019: 116 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $10 M offered; $2 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$688,887
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Ottavio Vitolo · Executive Officer · Chief Medical Officer
  • Sergio Traversa · Executive Officer, Director · CEO
  • Charles Casamento · Director · Chairman of the Board
  • Maged Shenouda · Director
  • Paul Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Brookline Capital Markets, A division of Arcadia Securities, LLC (CRD 44656) · New York, New YorkSold in AK, AL, AZ, CA, CO, GA, MD, MI, MS, NC, NJ, NV, NY, OH, PA, TX, WY
  • Alexander Capital, LP (CRD 40077) · New York, New YorkSold in AL, AZ, CA, CO, CT, FL, GA, IL, IN, KY, MA, MD, MN, NJ, NY, OR, PA, RI, SC, TX

Remarks in the notice

  • On fees: “Alexander Capital and Brookline received a cash fee (excluding expenses) of $518,687 and $170,200, respectively, and warrants to purchase an aggregate of 427,817 shares of common stock.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Sergio Traversa, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Jul 10, 2019. Read the notice at the SEC.

equity, optionsSEC
May 2019$3 MPrivate placement after listing$2 to $10 million

CAMP Nine, Inc.: Private sale, May 2019

Investors in this round

43 investors had bought by the notice of May 16, 2019: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $10 M offered; $7 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$221,150
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Ottavio Vitolo · Executive Officer · Chief Medical Officer
  • Sergio Traversa · Executive Officer, Director · CEO
  • Charles Casamento · Director · Chairman of the Board
  • Maged Shenouda · Director
  • Paul Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Alexander Capital, LP (CRD 40077) · New York, New YorkSold in AZ, CA, FL, GA, MD, NJ, NV, NY, SC, WY
  • Brookline Capital Markets, A division of CIM Securities, LLC (CRD 120852) · New York, New YorkSold in AL, CA, FL, MD, NJ, NV, NY, OH, SC, TX, WY

Remarks in the notice

  • On fees: “Alexander Capital and Brookline received a cash fee (excluding expenses) of $72,650 and $148,500, respectively, and warrants to purchase an aggregate of 147,433 shares of common stock.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Sergio Traversa, Ceo. Source: SEC Form D, newest notice filed May 16, 2019. Read the notice at the SEC.

equity, optionsSEC
Oct 2018$6 MPrivate placement after listing$2 to $10 million

CAMP Nine, Inc.: Private sale, Oct 2018

Investors in this round

66 investors had bought by the notice of Dec 10, 2018: 66 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $10 M offered; $4 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$563,861
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Ottavio Vitolo · Executive Officer
  • Sergio Traversa · Executive Officer, Director
  • Charles Casamento · Director
  • Maged Shenouda · Director
  • Paul Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Alexander Capital, LP (CRD 40077) · New York, New YorkSold in AZ, CA, CO, CT, FL, GA, MA, MD, NJ, NV, NY, OR, PA, RI, SC, TX, VT

Remarks in the notice

  • On fees: “Included in the sales commission amount is a non-accountable 1% allowance ($49,392) for expenses paid to the agent and a $20,000 upfront due diligence fee. The agent also received warrants to purchase 854,334 shares of common stock of the issuer.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Sergio Traversa, Ceo. Source: SEC Form D and 2 amendments, newest notice filed Dec 10, 2018. Read the notice at the SEC.

equity, optionsSEC
Sep 2017$7 MPrivate placement after listing$2 to $10 million

CAMP Nine, Inc.: Private sale, Sep 2017

Investors in this round

65 investors had bought by the notice of Oct 6, 2017: 65 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
$5,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$584,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Sergio Traversa · Executive Officer, Director
  • Charles Casamento · Director
  • Maged Shenouda · Director
  • Paul Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Alexander Capital, LP (CRD 40077) · New York, New YorkSold in AL, CO, CT, FL, GA, MA, NJ, NY, PA, RI, SC, TX, VA

Remarks in the notice

  • On fees: “Not included in the sales commission amount is a non-accountable 1% allowance ($58,540) for expenses paid to the agent. The agent also received warrants to purchase 779,333 shares of common stock of the issuer.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Sergio Traversa, Ceo. Source: SEC Form D, newest notice filed Oct 6, 2017. Read the notice at the SEC.

debt, optionsSEC
Jun 2014$11 MNo. 1$10 to $50 million

CAMP Nine, Inc.: Raise no. 1, Jun 2014

Investors in this round

236 investors had bought by the notice of Jun 19, 2014: 236 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
$100,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,069,458
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Douglas O. Beck · Executive Officer · Chief Financial Officer
  • Eliseo O. Salinas · Executive Officer · President and Chief Scientific Officer
  • Sergio Traversa · Executive Officer, Director · Chief Executive Officer
  • Nabil M. Yazgi · Director
  • Sandesh O. Seth · Director · Lead Director
  • Shreeram O. Agharkar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in AL, AZ, CA, CT, DE, FL, GA, IL, KS, LA, MA, MD, ME, MI, MN, MO, MT, NC, NE, NH, NJ, NV, NY, OH, OK, PA, RI, SC, TN, TX, VA, WI

Remarks in the notice

  • On fees: “Not included in the sales commission amount is a non-accountable 2% allowance for expenses paid to the agent. The agent also received warrants to purchase 1,782,431 shares of common stock of the issuer.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Sergio Traversa, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 19, 2014. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CAMP Nine, Inc. had no revenue when it filed its newest notice of a funding round (Jul 2019).

    SEC Form D (revenue range) · Jul 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2019

Products and services#

No products or services of CAMP Nine, Inc. are on record.

Investors#

No investor of CAMP Nine, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 236 investors.

Largest shareholders today

Institutions holding Relmada Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CAMP Nine, Inc.
NameRoleNamed in
Ottavio VitoloChief Medical OfficerJul 2019
Sergio TraversaCEOJul 2019
Douglas O. BeckChief Financial OfficerJun 2014
Eliseo O. SalinasPresident and Chief Scientific OfficerJun 2014
Charles CasamentoChairman of the BoardJul 2019
Maged ShenoudaDirectorJul 2019
Paul KellyDirectorJul 2019
Sergio TraversaCEOJul 2019
Nabil M. YazgiDirectorJun 2014
Sandesh O. SethLead DirectorJun 2014
Shreeram O. AgharkarDirectorJun 2014

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.